Close Menu

Monday, October 5

Browsing: nivolumab

Survivors

Reviewing the CheckMate 9DW Trial of Nivolumab Plus Ipilimumab in Unresectable HCC

By NewsCancerJuly 24, 20260

Ronan W. Hsieh, MD, presents the CheckMate 9DW trial for Team Chicago Hot Dog, reviewing the phase 3 study of…

Research

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)

By NewsCancerJuly 18, 20260

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12–49. Google Scholar Descamps G, Karaca…

Survivors

Post-Surgery Nivolumab Shows No DFS Improvement in EGFR/ALK-Negative NSCLC

By NewsCancerJune 1, 20260

Administering nivolumab (Opdivo) after standard-of-care adjuvant therapy did not improve disease-free survival (DFS) compared with best supportive care among patients…

Support

Low dose nivolumab helps head, neck cancer patients live longer

By NewsCancerMay 31, 20260

CHICAGO — What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is…

Research

Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma

By NewsCancerMarch 22, 20260

Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The Global Landscape of Esophageal Squamous…

Research

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

By NewsCancerMarch 16, 20260

Competing interests K.S. reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda Pharmaceutical, Ono Pharmaceutical,…

Research

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

By NewsCancerMarch 1, 20260

MOONLIGHT evolved into a platform trial of sequential, randomized and single-arm cohorts investigating the combination of dual immunotherapy with FOLFOX…

Research

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

By NewsCancerMarch 1, 20260

Competing interests M.S.v.d.H. has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE trial. C.H., S.K.C., S.S. and…

What's Hot

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

Berzosertib Combo Shows No Response Benefit in Metastatic CRPC

Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens

Browsing: nivolumab

Reviewing the CheckMate 9DW Trial of Nivolumab Plus Ipilimumab in Unresectable HCC

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)

Post-Surgery Nivolumab Shows No DFS Improvement in EGFR/ALK-Negative NSCLC

Low dose nivolumab helps head, neck cancer patients live longer

Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

Berzosertib Combo Shows No Response Benefit in Metastatic CRPC

Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens

Cancer-fighting t cells burn out. Scientists may have found a fix

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

Berzosertib Combo Shows No Response Benefit in Metastatic CRPC

Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens

Cancer-fighting t cells burn out. Scientists may have found a fix

Latest Post

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

Berzosertib Combo Shows No Response Benefit in Metastatic CRPC

Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens

Subscribe to Updates

What's Hot

Browsing: nivolumab